摘要
目的对近年来关于内源性大麻素系统在肝脏疾病中的作用及相关机制的研究做整理分析。方法查阅近年来的国内外文献,进行全面综合、整理和归纳。结果综述了内源性大麻素在肝病发生发展中的重要作用,重点阐述了其在病毒性肝炎、酒精性脂肪肝、非酒精性脂肪肝病、胆汁淤积性肝病及肝脏缺血再灌注损伤中的预防与保护作用以及调控肝纤维化的发生发展及肝病并发症肝性脑病的发病过程。结论内源性大麻素系统在肝病的治疗中具有重要作用,但作用机制复杂,亟待更深入的研究。
OBJECTIVE To analyze recent studies on the role of the endocannabinoid system in liver disease and related mecha- nism. METHODS Reading domestic and international documents in recent years, we concluded a comprehensive integrated about them. RESULTS This paper reviews the important role of the endocannabinoid in the development of liver disease, which focuses on the prevention and protection of the endocannabinoid on viral hepatitis, alcoholic fatty liver disease, non-alcoholic fatty liver disease, cholestatic liver disease and liver ischemia-reperfusion injury and the development of hepatic fibrosis and hepatic encephalopathy. CONCLUSION Endocannabinoid system plays an important role in the treatment of liver disease. But for its complex mechanism of action, we need further research.
出处
《中国药学杂志》
CAS
CSCD
北大核心
2014年第2期89-93,共5页
Chinese Pharmaceutical Journal
基金
国家自然科学基金资助项目(81270514
30873424)
教育部博士点基金(20103237110010)
江苏省六大人才基金(2009-B-010)
江苏高校优势学科建设工程资助项目(ysxk-2010)
南京中医药大学中药学一级学科开放课题资助(2011ZYX4-008)
十一五科技支撑计划(2008BAI51B02)
关键词
内源性大麻素系统
酒精性脂肪肝
非酒精性肝病
胆汁淤积性肝病
缺血
再灌注损伤
肝纤维化
肝性脑病
endogenous cannabinoid system
alcoholic fatty liver
non-alcoholic fatty liver disease
cholestatic liver disease
he-patic ischemia/reperfusion injury
hepatic fibrosis
hepatic encephalopathy
